MedDataX Logo

Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi

NCT ID: NCT00862914

Last Updated: 2012-10-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2008-07-31

Study Completion Date

2009-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation. miRNAs bind to their target messenger RNAs (mRNAs), leading to cleavage or suppression of target mRNA translation based on the degree of complementarity. miRNAs have recently been shown to play pivotal roles in diverse developmental and cellular processes and linked to a variety of skin diseases and cancers. In the present study the researchers investigate the immunohistochemical distribution of Dicer in benign and dysplastic melanocytic naevi as well as in cutaneous malignant melanoma compared to intraindividual healthy control.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Naevi Malignant Melanoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Skin MicroRNA miRNA Dicer Malignant Melanoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

benign melanocytic naevi

No interventions assigned to this group

2

dysplastic melanocytic naevi

No interventions assigned to this group

3

cutaneous malignant melanoma

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with benign melanocytic naevi, dysplastic melanocytic naevi and cutaneous malignant melanoma.

Exclusion Criteria

* Patients under 18 years of age
* Patients with other forms of cancer in previous medical history
* Pregnancy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ruhr University of Bochum

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Michael Sand

Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Prof. Dr. Peter Altmeyer

Role: PRINCIPAL_INVESTIGATOR

Department of Dermatology and Allergology, Ruhr-University Bochum

PD Dr. Falk G. Bechara

Role: STUDY_DIRECTOR

Department of Dermatology and Allergology, Ruhr-University Bochum

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Dermatology and Allergology, Ruhr-University Bochum

Bochum, North Rhine-Westphalia, Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

References

Explore related publications, articles, or registry entries linked to this study.

Sand M, Gambichler T, Sand D, Altmeyer P, Stuecker M, Bechara FG. Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi. Eur J Dermatol. 2011 Jan-Feb;21(1):18-21. doi: 10.1684/ejd.2011.1210.

Reference Type RESULT
PMID: 21262599 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

006

Identifier Type: -

Identifier Source: org_study_id